TG Therapeutics (TGTX) Short Interest Ratio & Short Volume $34.20 -1.27 (-3.58%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$34.21 +0.01 (+0.04%) As of 06:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock TG Therapeutics Short Interest DataTG Therapeutics (TGTX) has a short interest of 23.11 million shares. This marks a -1.83% decrease in short interest from the previous month. The short interest ratio (days to cover) is 7.7, indicating that it would take 7.7 days of the average trading volume of 2.98 million shares to cover all short positions.Current Short Interest23,110,000 sharesPrevious Short Interest23,540,000 sharesChange Vs. Previous Month-1.83%Dollar Volume Sold Short$1.05 billionShort Interest Ratio7.7 Days to CoverLast Record DateApril 30, 2025Outstanding Shares158,755,000 sharesPercentage of Shares Shorted14.56%Today's Trading Volume1,942,081 sharesAverage Trading Volume2,981,519 sharesToday's Volume Vs. Average65% Short Selling TG Therapeutics? Sign up to receive the latest short interest report for TG Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartTGTX Short Interest Over TimeTGTX Days to Cover Over TimeTGTX Percentage of Float Shorted Over Time TG Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202523,110,000 shares $1.05 billion -1.8%N/A7.7 $45.51 4/15/202523,540,000 shares $918.77 million -5.4%16.9%8.8 $39.03 3/31/202524,890,000 shares $981.41 million -5.1%17.6%9 $39.43 3/15/202526,230,000 shares $1.07 billion +1.1%18.6%10.3 $40.84 2/28/202525,950,000 shares $780.84 million +0.8%18.4%10.7 $30.09 2/15/202525,740,000 shares $790.48 million -4.2%18.4%11.9 $30.71 1/31/202526,880,000 shares $852.10 million -2.7%19.3%10.1 $31.70 1/15/202527,630,000 shares $833.87 million +6.3%19.7%9.4 $30.18 12/31/202425,990,000 shares $782.30 million -4.2%18.5%9 $30.10 12/15/202427,140,000 shares $869.02 million -6.7%19.3%9.4 $32.02 Get the Latest News and Ratings for TGTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for TG Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/30/202429,080,000 shares $1.01 billion +2.7%20.7%8.1 $34.80 11/15/202428,330,000 shares $836.87 million -11.5%20.2%7.5 $29.54 10/31/202432,000,000 shares $801.92 million -1.5%23.1%8.9 $25.06 10/15/202432,480,000 shares $798.03 million -5.6%23.5%9.2 $24.57 9/30/202434,400,000 shares $804.62 million +15.3%24.9%9.5 $23.39 9/15/202429,840,000 shares $708.10 million +1.1%21.6%8.2 $23.73 8/31/202429,510,000 shares $693.19 million -9.8%21.4%9.6 $23.49 8/15/202432,720,000 shares $685.16 million +5.0%23.7%11.4 $20.94 7/31/202431,170,000 shares $615.92 million -3.1%22.6%11.2 $19.76 7/15/202432,180,000 shares $684.47 million -1.6%23.4%10.4 $21.27 6/30/202432,700,000 shares $581.73 million -2.6%23.8%10.6 $17.79 6/15/202433,560,000 shares $555.42 million +0.6%24.4%11 $16.55 5/31/202433,350,000 shares $543.61 million -2.8%24.2%10.9 $16.30 5/15/202434,300,000 shares $607.80 million -9.4%24.9%9.4 $17.72 4/30/202437,850,000 shares $517.03 million +6.0%27.1%10 $13.66 4/15/202435,710,000 shares $502.44 million +3.9%25.6%10.3 $14.07 3/31/202434,360,000 shares $522.62 million +0.5%24.7%7.9 $15.21 3/15/202434,190,000 shares $520.37 million -1.9%24.5%7.2 $15.22 2/29/202434,840,000 shares $599.94 million -2.6%25.0%6.7 $17.22 2/15/202435,780,000 shares $515.23 million +22.9%26.2%7.2 $14.40 1/31/202429,120,000 shares $472.91 million -5.2%21.4%5.6 $16.24 1/15/202430,700,000 shares $484.14 million -3.6%22.5%4.7 $15.77 12/31/202331,830,000 shares $543.66 million -12.8%23.2%5.2 $17.08 12/15/202336,520,000 shares $674.89 million +1.7%26.6%6.3 $18.48 11/30/202335,920,000 shares $460.14 million -1.9%26.2%6.4 $12.81 11/15/202336,610,000 shares $412.59 million -1.1%26.7%6.8 $11.27 10/31/202337,020,000 shares $286.16 million -0.5%27.0%6.8 $7.73 10/15/202337,210,000 shares $248.93 million +14.5%27.2%7.2 $6.69 9/30/202332,510,000 shares $271.78 million +10.2%23.7%6.5 $8.36 9/15/202329,510,000 shares $299.23 million +5.5%21.5%6 $10.14The DOJ Just Said Your Money Isn’t Yours (Ad)What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.Get your free guide now by clicking here >> 8/31/202327,970,000 shares $292.85 million +1.6%20.4%5.8 $10.47 8/15/202327,520,000 shares $317.31 million +19.2%20.1%5.8 $11.53 7/31/202323,080,000 shares $477.53 million +3.3%16.9%5 $20.69 7/15/202322,340,000 shares $493.71 million -1.1%16.5%5.7 $22.10 6/30/202322,580,000 shares $560.89 million +0.4%16.7%5.5 $24.84 6/15/202322,480,000 shares $595.27 million +0.2%16.6%5.4 $26.48 5/31/202322,430,000 shares $597.31 million +3.0%16.6%5.2 $26.63 5/15/202321,770,000 shares $678.14 million -15.0%16.1%5.1 $31.15 4/30/202325,610,000 shares $635.90 million -6.7%19.3%5.8 $24.83 4/15/202327,460,000 shares $557.99 million -3.4%20.7%6.6 $20.32 3/31/202328,420,000 shares $427.44 million +6.6%21.5%6.3 $15.04 3/15/202326,650,000 shares $394.15 million +2.6%20.1%4.7 $14.79 2/28/202325,970,000 shares $416.04 million +6.3%19.1%4.6 $16.02 2/15/202324,440,000 shares $472.67 million +4.2%18.1%4.5 $19.34 1/31/202323,450,000 shares $357.14 million +4.0%17.4%4.3 $15.23 1/15/202322,560,000 shares $307.49 million -3.3%16.7%4.4 $13.63 12/30/202223,340,000 shares $276.11 million +12.9%17.3%4.9 $11.83 12/15/202220,680,000 shares $178.26 million +6.9%15.3%7 $8.62 11/30/202219,350,000 shares $170.67 million -1.7%14.4%7.2 $8.82 11/15/202219,680,000 shares $173.38 million +2.3%14.6%7.6 $8.81 10/31/202219,230,000 shares $111.92 million -1.1%14.3%7.9 $5.82 10/15/202219,440,000 shares $105.56 million +5.8%14.5%7.6 $5.43 9/30/202218,380,000 shares $108.81 million +3.8%13.7%7 $5.92 9/15/202217,710,000 shares $129.28 million -3.1%13.2%6.6 $7.30 8/31/202218,270,000 shares $130.27 million -3.5%13.6%6.3 $7.13 8/15/202218,940,000 shares $159.10 million -7.1%14.1%5.9 $8.40 7/31/202220,380,000 shares $122.08 million -2.3%15.3%6.2 $5.99 7/15/202220,860,000 shares $129.33 million +0.2%28.8%6.6 $6.20 6/30/202220,810,000 shares $88.44 million +2.5%28.7%6.3 $4.25 6/15/202220,310,000 shares $78.60 million +5.6%28.0%6.4 $3.87 5/31/202219,240,000 shares $85.04 million -2.6%14.4%6.5 $4.42 5/15/202219,760,000 shares $128.44 million +1.2%14.8%7.8 $6.50 4/30/202219,530,000 shares $135.54 million +0.8%14.8%8.3 $6.94 4/15/202219,370,000 shares $171.42 million -8.1%14.6%6.9 $8.85 3/31/202221,070,000 shares $200.38 million +11.0%15.9%8.5 $9.51 3/15/202218,980,000 shares $151.65 million -3.8%14.3%7.8 $7.99 2/28/202219,720,000 shares $194.64 million +4.0%14.9%8.4 $9.87 2/15/202218,970,000 shares $207.34 million +13.9%14.3%7.1 $10.93 1/31/202216,660,000 shares $192.76 million +2.0%12.5%6.4 $11.57 1/15/202216,340,000 shares $256.37 million +6.4%12.3%8.6 $15.69 12/31/202115,360,000 shares $291.84 million +5.8%N/A8.8 $19.00 12/15/202114,520,000 shares $242.77 million +8.5%11.0%8.9 $16.72 11/30/202113,380,000 shares $203.38 million -1.2%10.1%8.7 $15.20 11/15/202113,540,000 shares $366.26 million +0.6%10.2%11.6 $27.05 10/29/202113,460,000 shares $420.22 million -1.7%10.2%10.7 $31.22 10/15/202113,690,000 shares $456.01 million +1.3%10.4%9.1 $33.31 9/30/202113,520,000 shares $449.95 million +4.1%10.2%8.9 $33.28 9/15/202112,990,000 shares $388.40 million -6.2%9.8%8.6 $29.90 8/31/202113,850,000 shares $374.92 million +8.0%10.5%9.4 $27.07 8/13/202112,820,000 shares $292.17 million +12.2%9.7%9.2 $22.79AI Bloodbath Coming on June 1st? (Ad)If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new invention… This could send many popular AI stocks crashing, including Nvidia. And it could happen starting as soon as June 1st.Click here to see the details and learn how to prepare for the next AI revolution 7/30/202111,430,000 shares $399.94 million +3.5%8.7%8.6 $34.99 7/15/202111,040,000 shares $411.02 million +2.5%8.4%9.8 $37.23 6/30/202110,770,000 shares $417.77 million -5.8%8.2%8.5 $38.79 6/15/202111,430,000 shares $427.60 million -2.8%8.7%8.3 $37.41 5/28/202111,760,000 shares $410.07 million +1.8%8.9%8.3 $34.87 5/14/202111,550,000 shares $395.47 million +2.6%8.8%8 $34.24 4/30/202111,260,000 shares $484.41 million +0.8%8.5%7.7 $43.02 4/15/202111,170,000 shares $497.85 million -5.4%8.5%7.5 $44.57 3/31/202111,810,000 shares $534.76 million -1.3%9.0%8.1 $45.28 3/15/202111,960,000 shares $595.97 million +1.0%9.1%7.9 $49.83 2/26/202111,840,000 shares $515.04 million +0.7%9.1%5.7 $43.50 2/12/202111,760,000 shares $574.01 million -2.1%9.2%5.8 $48.81 1/29/202112,010,000 shares $577.08 million -4.4%9.4%5.9 $48.05 1/15/202112,560,000 shares $642.95 million No Change9.8%6.3 $51.19 TGTX Short Interest - Frequently Asked Questions What is TG Therapeutics' current short interest? Short interest is the volume of TG Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, traders have sold 23,110,000 shares of TGTX short. Learn More on TG Therapeutics' current short interest. What is a good short interest ratio for TG Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. TGTX shares currently have a short interest ratio of 8.0. Learn More on TG Therapeutics's short interest ratio. Which institutional investors are shorting TG Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of TG Therapeutics: Jane Street Group LLC, Cubist Systematic Strategies LLC, Caption Management LLC, Jane Street Group LLC, Walleye Trading LLC, Walleye Capital LLC, and Capital Fund Management S.A.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is TG Therapeutics' short interest increasing or decreasing? TG Therapeutics saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 23,110,000 shares, a drop of 1.8% from the previous total of 23,540,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does TG Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to TG Therapeutics: Teva Pharmaceutical Industries Limited (2.51%), Summit Therapeutics Inc. (3.66%), Intra-Cellular Therapies, Inc. (2.58%), Genmab A/S (0.39%), Dr. Reddy's Laboratories Limited (1.79%), Viatris Inc. (4.27%), Moderna, Inc. (17.58%), Qiagen (2.35%), Ascendis Pharma A/S (6.40%), Roivant Sciences Ltd. (12.03%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Spotify Technology S.A. ($4.67 billion), Charter Communications, Inc. ($4.58 billion), Capital One Financial Co. ($4.47 billion), The Kroger Co. ($2.56 billion), Reddit, Inc. ($2.23 billion), Rivian Automotive, Inc. ($2.16 billion), Live Nation Entertainment, Inc. ($1.90 billion), SoFi Technologies, Inc. ($1.85 billion), Zscaler, Inc. ($1.75 billion), and Omnicom Group Inc. ($1.75 billion). View all of the most shorted stocks. What does it mean to sell short TG Therapeutics stock? Short selling TGTX is an investing strategy that aims to generate trading profit from TG Therapeutics as its price is falling. TGTX shares are trading down $1.27 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against TG Therapeutics? A short squeeze for TG Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of TGTX, which in turn drives the price of the stock up even further. How often is TG Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including TGTX, twice per month. The most recent reporting period available is April, 30 2025. More Short Interest Resources from MarketBeat Related Companies Teva Pharmaceutical Industries Short Interest Summit Therapeutics Short Interest Intra-Cellular Therapies Short Interest Genmab A/S Short Interest Dr. Reddy's Laboratories Short Interest Viatris Short Interest Moderna Short Interest Qiagen Short Interest Ascendis Pharma A/S Short Interest Roivant Sciences Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:TGTX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TG Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TG Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TGTX Stock Free TGTX Stock Alerts